WO2005007167A1 - 固形製剤 - Google Patents
固形製剤 Download PDFInfo
- Publication number
- WO2005007167A1 WO2005007167A1 PCT/JP2004/010530 JP2004010530W WO2005007167A1 WO 2005007167 A1 WO2005007167 A1 WO 2005007167A1 JP 2004010530 W JP2004010530 W JP 2004010530W WO 2005007167 A1 WO2005007167 A1 WO 2005007167A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solid preparation
- preparation according
- acceptable salt
- weight
- tablet
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
Definitions
- the present invention relates to a solid preparation containing a xanthine derivative or a pharmacologically acceptable salt thereof.
- a xanthine derivative represented by the following formula (I) [hereinafter referred to as compound (I)] or a pharmacologically acceptable salt thereof exhibits an adenosine A 2 receptor antagonistic action, and adenosine A 2 It is known to be useful for the treatment of various diseases based on receptor hyperactivity, for example, Parkinson's disease, senile dementia, depression and the like (for example, European Patent No. 0590919).
- An object of the present invention is to provide a solid preparation containing compound (I) or a pharmacologically acceptable salt thereof, which is excellent in preparation properties (for example, hardness, disintegration, dissolution, stability, etc.). is there.
- the present invention relates to the following (1) to (22).
- R 4 represents cycloalkyl, mono (CH 2 ) n — R 5 , wherein represents a substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group.
- N represents an integer of 0 to 4) or the formula (II)
- Y 1 and Y 2 are the same or different and represent a hydrogen atom, a halogen atom or a lower alkyl, and z represents a substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group).
- R 4 is the formula (II)
- Upsilon 1 and Upsilon 2 is the hydrogen atom (2) the solid preparation according.
- R 6 represents a hydrogen atom, hydroxy, lower alkyl, lower alkoxy, halogen, nitro or amino, and m represents an integer of 1 to 3).
- Equation (IA) (E) -8- (3,4-Dimethoxystyryl)-1,3-Getyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or its pharmacology A solid preparation containing a chemically acceptable salt and microcrystalline cellulose.
- the disintegrant is crospovidone, croscarmellose sodium, low-substituted hydroxypropinoresenololose, canolemelose kanoresium or sodium starch glycolate (16) ).
- Examples of the lower alkyl moiety of the lower alkyl and the lower alkoxy include a straight-chain or branched alkyl having 1 to 6 carbon atoms, and specifically, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and the like. sec-butinore, tert-putinore, pentinore, neopentyl, hexinole, etc.
- the lower alkenyl includes, for example, straight chain or branched alkenyl having 2 to 6 carbon atoms, and specifically, vinyl, aryl, methacryl, crotinol, 3-buteninole, 2-penteninole , 4-penteninole, 2-hexeninole, 5-hexenyl and the like. '
- the lower alkynyl includes, for example, straight-chain or branched alkynyl having 2 to 6 carbon atoms, and specific examples thereof include ethur, propargyl, 2-butynyl, 3-pentinole, 2-pentinole, and 2-pentynole. 4-pentynole, 2-hexynole, 5-hexyl, 4-methyl-2-pentynole, and the like.
- cycloalkyl examples include cycloalkyl having 3 to 8 carbon atoms.Specifically, cyclopropyl propyl, cyclopentyl, cyclopentyl ', cyclohexyl, cycloheptyl, And cyclooctinole.
- Halogen means atoms of fluorine, chlorine, bromine and iodine.
- aryl examples include aryl having 6 to 14 carbon atoms, and specific examples include phenyl, naphthyl, and anthryl.
- heterocyclic group for example, a 5- or 6-membered monocyclic heterocyclic group containing at least one atom selected from a nitrogen atom, an oxygen atom and a sulfur atom, or a fused 3- to 8-membered ring
- examples include bicyclic or tricyclic condensed heterocyclic groups containing at least one atom selected from a nitrogen atom, an oxygen atom, and a sulfur atom, and specifically, furyl, chel, pyrrolyl, and viranyl.
- the substituents in the substituted aryl and the substituted heterocyclic groups may be the same or different, for example, having 1 to 3 substituents, specifically, lower alkyl, lower alkenyl, lower alkynyl, hydroxy, substituted or Unsubstituted lower alkoxy, halogen, nitro, amino, lower alkylamino, di-lower alkylamino, triphenylenomethyl, triphenylenomethoxy, aralkyl, aralkyloxy, aryl, aryl Luoxy, lower alkanoyl, lower alkanoyloxy, aroyl, aroyloxy, arylalkanoyloxy, carboxy, lower alkoxycarbonyl, lower alkyl rubamoyl, di-lower alkyl rubamoyl, sulfo, lower alkoxysulfonyl, lower Alkylsulfamoyl, di-lower Gravel / Les Roh referencing Moi Nor
- the lower alkyl part of amoyl-di-lower alkylsulfamoyl has the same meaning as the lower alkyl, and halogen, lower alkenyl and lower alkyl have the same meanings as above.
- di-lower alkylamino di-lower alkyl radicals
- the two lower alkyl moieties may be the same or different.
- the aryl portion of the aryloxy is synonymous with the aryl, and the aralkyl portion of the aralkyl includes, for example, benzyl, phenethyl and the like.
- Examples of the aroyl portion of aroyl and aroyloxy include benzoyl and naphthyl.
- Examples of the arylalkyl moiety of arylalkanoyloxy include benzyl, phenethyl and the like.
- Substituents in the substituted lower alkoxy may be the same or different and include, for example, 1 to 3 substitutions, specifically, hydroxy, lower alkoxy, halogen, amino, azide, carbonyl, lower alkoxycarbonyl and the like. can give.
- the lower alkyl moiety of the lower alkoxy and the lower alkoxy group is as defined above, and the halogen is as defined above.
- Examples of the pharmacologically acceptable salt of compound (I) include pharmacologically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts, and amino acid addition salts.
- pharmacologically acceptable acid addition salts include pharmacologically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts, and amino acid addition salts.
- Pharmaceutically acceptable acid addition salts of compound (I) include, for example, inorganic salts such as hydrochloride, sulfate, phosphate, acetate, maleate, fumarate, tartrate, and the like. Organic salts such as citrate and methanesulfonate are listed.
- pharmacologically acceptable metal salts include alkali metal salts such as sodium salt and potassium salt, and the like. Alkaline earth metal salts such as magnesium salts and calcium salts, aluminum salts, zinc salts, and the like.
- Examples of pharmacologically acceptable ammonium salts include, for example, ammonium and tetramethylammonium.
- Pharmacologically acceptable organic amine addition salts include, for example, morpholin, piperidine and the like, and pharmacologically acceptable amino acid addition salts.
- morpholin for example, resin, dalysin, and quini And addition salts such as guaranine.
- Compound (I) or a pharmacologically acceptable salt thereof for example, a compound of the formula (IA) (E) -8- (3,4-Dimethoxystyryl)-1,3-getyl-7-methyl-3,7-dihydro-1H-purin-2,6-dione (compound 1)
- the method for producing a pharmacologically acceptable salt thereof is not particularly limited.For example, the methods described in JP-A-6-211856, EP-A-0590919, JP-A-9-040652 or the like It can be obtained by a method according to.
- Compound (I) or a pharmacologically acceptable salt thereof can be used in the solid preparation of the present invention in any form of powder, crystal, or bulk as long as it is solid, and is not particularly limited.
- Examples thereof include crystalline compound (I) having a crystallinity of 20% or more or a pharmacologically acceptable salt thereof.
- a crystalline compound (I) having a crystallinity of 30% or more or a pharmacologically acceptable salt thereof is preferable, and a crystalline compound (I) having a crystallinity of 40% or more or a drug thereof is preferable.
- Physiologically acceptable salts are preferred.
- crystallinity of compound (I) or a pharmacologically acceptable salt thereof is defined as “crystallinity of compound (I) or pharmacologically acceptable salt thereof” in “compound (I) or pharmacologically acceptable salt thereof”. It means the content of "the pharmacologically acceptable salt” and is calculated by the following formula.
- the amount of “compound (I) or a pharmaceutically acceptable salt thereof” is defined as “a crystalline compound (I) or a pharmaceutically acceptable salt thereof” and “amorphous compound 1 or Means the pharmacologically acceptable salt ".
- the crystallinity is calculated, for example, by measuring the integrated intensity of a diffraction peak at a specific diffraction angle of 2 ° using a powder X-ray diffractometer (for example, JDX8030; manufactured by Nippon Denshi Co., Ltd.).
- the degree of crystallinity is based on the integrated intensity of the diffraction peak of a standard sample (100% crystallinity) in which the content of “crystalline compound (I) or a pharmaceutically acceptable salt thereof” is 100%. Measurement It is obtained as the ratio of the integrated intensity of the diffraction peak of the sample.
- crystalline compounds (I) or pharmacologically acceptable salts thereof can be prepared, for example, by the methods described in JP-A-6-211856, EP-A-0590919, JP-A-9-040652 and the like. Or it can be obtained by a method according to them.
- the crystalline compound (I) having a crystallinity of 20% or more and the pharmaceutically acceptable salts thereof the crystalline compound (I) having an average particle size of less than 50 ⁇ or the crystalline compound (I) A pharmacologically acceptable salt is preferred.
- a crystalline compound (I) having an average particle size of 0.5 to 20 ⁇ m and a crystallinity of 20% or more or a pharmacologically acceptable salt thereof Salts are preferred.
- These average particle diameters can be calculated, for example, using a laser diffraction / disturbance type particle size distribution analyzer (for example, MASTERSIZER 2000 Ver.2.00 J; manufactured by MALVERN) or an image analyzer (for example, LUZEX® AP; It is measured by using Reco, etc.) and calculated as the average value obtained from the particle size distribution.
- a laser diffraction / disturbance type particle size distribution analyzer for example, MASTERSIZER 2000 Ver.2.00 J; manufactured by MALVERN
- an image analyzer for example, LUZEX® AP; It is measured by using Reco, etc.
- These have a degree of crystallinity of at least 20% obtained by the method described in, for example, JP-A-6-211856, EP 0590919, JP-A-9-040652, or a method analogous thereto. It is prepared by pulverizing and / or sieving a certain crystalline compound (I) or a pharmacologically acceptable salt thereof.
- the pulverization, crushing and Z or sieving may be performed several times in an appropriate combination. . Crushing can be performed using a commonly used crusher, for example, a mortar, Mechano Mill® (manufactured by Okada Seie Co., Ltd.), jet mill or the like.
- the pulverization conditions such as the rotation speed of the pulverizer, the supply rate of the crystalline compound (I) having a crystallinity of 20% or more or the pharmacologically acceptable salt thereof, and the pulverization time are determined.
- the compound (I) having a desired average particle size and Z or crystallinity or a pharmacologically acceptable salt thereof can be obtained by appropriately adjusting.
- the supply rate of the crystalline compound (I) having a crystallinity of 20% or more or a pharmacologically acceptable salt thereof is 10 to:! OOg / min, and the pulverization pressure is 0.01.
- crystalline compound (I) or a pharmacologically acceptable salt thereof having a crystallinity of 20% or more can be ground.
- the content of compound (I) or a pharmacologically acceptable salt thereof in the solid preparation of the present invention is not particularly limited.
- compound 1 preferably 1 to 50% of the total weight of the solid preparation, Preferably it is 2 to 30%, more preferably 5 to 20%.
- crystalline cellulose those usually used in oral dosage forms Any of these may be used as long as it is not particularly limited.
- commercially available crystalline cellulose, powdered cellulose, and the like are used.
- the content of crystalline cellulose in the solid preparation of the present invention is not particularly limited, but is preferably 1 to 75%, more preferably 5 to 50%, more preferably 10 to 30% of the total weight of the solid preparation. It is. '
- the solid preparation of the present invention may contain additives usually used in preparations for oral administration, for example, solid preparations containing excipients such as starch and saccharides, binders, and disintegrants are preferable. Among the excipients, saccharides are preferred.
- the saccharide may be any of those normally used in formulations for oral administration, and is not particularly limited.Examples include lactose, sucrose, glucose, cyclodextrin, mannitol, and the like. Is preferred. '
- the content of the saccharide in the solid preparation of the present invention is not particularly limited, but is preferably 1 to 95%, more preferably 5 to 80%, and still more preferably 20 to 65% of the total weight of the solid preparation.
- the mixing ratio of the saccharide to the crystalline cellulose in the solid preparation of the present invention is preferably 1.0 to 9.0 parts by weight for 1.0 part by weight of crystalline cellulose. Parts by weight, more preferably 1.0 to 5.0 parts by weight, even more preferably 1.5 to 3.0 parts by weight. .
- the binder may be any one which is usually used in a preparation for oral administration, and is not particularly limited.
- hydroxypropyl cellulose HPMC
- HPMC hydroxypropyl methylcellulose
- PVP polyvinyl pyrrolidone
- polyvinyl alcohol is particularly preferable.
- polybutyl alcohol those having a polymerization degree of 250 to 5,000 are preferable, and those having a polymerization degree of 500 to 5,000 are more preferable.
- the content of the binder in the solid preparation of the present invention is not particularly limited, but is preferably 0 :! To 10.0%, more preferably 0.5 to 7.0%, and still more preferably 1.0 to 5.0%.
- the disintegrant is not particularly limited as long as it is commonly used in oral preparations, and examples thereof include sodium alginate and croscarmellose sodium (trade names: Actizol, Asahi Kasei Corporation) -Co., Ltd.), sodium starch glycolate (trade name: Exprotab, Penwest Pharmaceuticals, etc.), low-substituted hydroxypropylcellulose, potassium noremelose calcium, clospovidone and the like are used, among which crospovidone is preferred.
- the content of the disintegrant in the solid preparation of the present invention is not particularly limited, but is preferably 0.5 to 20.0%, more preferably 1.0 to 15.0%, more preferably 3.0 to 10.0% of the total weight of the solid preparation. is there.
- Examples of the dosage form of the solid preparation of the present invention include tablets, capsules, granules and the like.
- the tablet of the present invention can be produced by a method generally used in the technical field of pharmaceuticals such as compression molding.
- the above-mentioned components are mixed by a mixer or the like.
- a compression tableting machine a tablet is formed by breaking the obtained mixture as it is, a granule is once prepared from each of the above components, and the obtained granule is tableted.
- Tableting pressure can be appropriately selected, for example, from the range of 300 to 3000 kg / cm 2 .
- the size of the tablet is not particularly limited, for example, a tablet having a weight per tablet of 20 to 3000 mg and a tablet diameter of 5 to 15 mm is preferable.
- the granules can be prepared by, for example, a wet granulation method or a dry granulation method.
- the wet granulation method include fluidized bed granulation, and more specifically, for example, (1) Compound (I) or a pharmacologically acceptable salt, saccharide, and crystalline cellulose for compound (I).
- the binder solution used for spraying include water, ethanol, isopropyl alcohol, or a solution in which the binder is dissolved in a mixed solvent thereof, and an aqueous solution of the binder is most preferable. .
- Examples of the dry granulation method include (1) forming flakes using a commercially available dry granulator, or forming pellets using a punching machine, and (2) obtaining the flakes or pellets on the market. And a method of obtaining granules by crushing with a crusher or a granulator.
- the preparation of granules can be performed, for example, in the same manner as in the method of preparing granules in the above-mentioned tablet production.
- the forcepsel preparation can be performed, for example, by filling granules obtained in the same manner as in the method for preparing granules in the above tablet production into forcepsel.
- the solid preparation of the present invention may be formed into a film by coating the granules, tablets and the like obtained above as a core with a coat (film-forming substance).
- the coating is not particularly limited as long as it is a coating composition containing a coating agent.
- the coating agent may be any of those usually used in oral preparations, and is not particularly limited. Examples thereof include those in which the active ingredient elutes immediately after administration of the solid preparation.
- a coating agent that is water-soluble, gastric-soluble, enteric-soluble, or the like is preferable.
- lactose HPMC, HPC, hydroxypropyl methylcellulose phthalate, polyethylene glycol cornole, polyphenol, 'ninoleanolonecole, polybieracetal ge / reamine acetate, hydroxypropyl pineolemethinolacenorelenolate Acesuccinate succinate, meta linoleic acid copolymer (trade name: Oy Dragit E, Oy, Dragit L, manufactured by Rohm and Pharma Co., Ltd.) and the like.
- the amount of the coating composition used is preferably 1 to 20 weight per core. /. And more preferably 3 to: 10% by weight. .
- the solid preparation of the present invention may further contain other commonly used additives such as a lubricant, a surfactant and a plasticizer, if necessary.
- a lubricant include magnesium stearate, calcium stearate, talc, light anhydrous silicic acid, and hydrated silicon dioxide.
- surfactants include phospholipids, glycerin fatty acid esters (eg, triacetin), sorbitan fatty acid esters, polyoxyethylene fatty acid esters, polyethylene daricol fatty acid esters, polyoxyethylene hydrogenated castor oil, and polyoxyethylene hardened castor oil. Oxyethylene alkyl ether, sucrose fatty acid ester and the like can be mentioned.
- the plasticizer include triacetin, vegetable oil, polyethylene glycol, and the like.
- these solid preparations can be mixed, if necessary, with well-known mixing, pulverization, sieving, granulation, sizing, tableting, drying, capsules, etc. It may be manufactured by appropriately combining formulation steps such as a filling step and a coating step.
- the stabilization method of the present invention can be carried out, for example, by the above-described method for preparing the solid preparation of the present invention. That is, by formulating compound (I) or a pharmacologically acceptable salt thereof so that crystalline cellulose is present. Can be implemented.
- the effects of the present invention will be specifically described by the following test examples.
- Example 1 Using a tablet hardness meter (PTB-311; manufactured by Pharmatest), the tablet hardnesses of the tablet 1 obtained in Example 1 and the tablets 2 and 3 obtained in Comparative Examples 1 and 2, respectively, were measured.
- PTB-311 a tablet hardness meter
- the crushing test was carried out on tablets 1 and 2 obtained in Example 1 and tablets 2 and 3 obtained in Comparative Examples 1 and 2, respectively.
- the time (relapse time) required was measured.
- the test was performed using purified water as a test solution.
- Table 1 shows the results of the tablet hardness measurement of Test Example 1 and the collapse test of Test Example 2.
- Tablet 3 23.6 26.5 From Table 1, it was found that Tablets 2 and 3, which have conventional general compositions, had a disintegration time of 20 minutes or more and did not rapidly disintegrate. On the other hand, it was found that Tablet 1 comprising the composition of the present invention had higher hardness than Tablets 2 and 3, and quickly collapsed in a short time.
- the tablet 1 obtained in Example 1 and the tablets 1 in Comparative Examples 1 and 2 were obtained, respectively.
- a dissolution test was performed on tablets 2 and 3 respectively. The test was performed using 900 mL of an aqueous solution of 2.0% by weight Tween80 (manufactured by Wako Pure Chemical Industries, Ltd.) at a paddle speed of 50 rpm. After the dissolution test was started, the test solution was sampled over time, and the amount of Compound 1 dissolved from each tablet was determined by high performance liquid chromatography (HPLC) analysis.
- HPLC analysis conditions are as follows. ⁇ HPLC analysis conditions>
- UV absorption photometer (measurement wavelength: 250nm)
- Figure 1 shows the results of the dissolution test. From Fig. 1, it was found that tablets 2 and 3 of conventional general composition did not show rapid elution. On the other hand, Tablet 1 comprising the composition of the present invention showed an elution rate of 80% or more in 30 minutes, indicating that Compound 1 was rapidly dissolved from Tablet 1.
- Test Example 4 Stability test of solid preparation
- Example 1 The tablets obtained in Example 1 according to the guidelines for photostability testing of new drug substances and new drugs at the International Conference on Harmonization of Approval for Trial Drugs (ICH) (November 6, 1996). In addition, stability tests were performed on the tablets 2 to 4 obtained in Comparative Examples 1 to 3, respectively. Using a xenon lamp as a light source, each tablet was exposed to a total illuminance of 12,000 Lux.hr or more. After exposure to light, sampling was performed, and the total amount of decomposed products of Compound 1 generated during the photolysis process in each preparation was determined by HPLC analysis. HPLC analysis conditions are the same as the conditions shown in Test Example 3.
- Table 2 shows the results of the stability test. Table 2 Results of stability test
- Table 2 shows that the production of degraded product of Compound 1 was significantly suppressed in Tablet 1 containing crystalline cellulose, as compared with Tablet 24 containing no crystalline cellulose. Turned out to be.
- the solid preparation of the present invention has excellent preparation properties such as good hardness, disintegration, dissolution, and stability.
- FIG. 1 shows the dissolution properties of Compound 1 in Tablet 1 obtained in Example 1 and Tablets 2 and 3 obtained in Comparative Examples 1 and 2, respectively.
- the vertical axis represents the elution rate (%) of Compound 1
- the horizontal axis represents the elution time (minute). The meaning of each symbol on the graph is as follows.
- Tablets were prepared as follows according to the formulation shown in Table 3 below. That is, compound 1 (230.8 g) obtained according to the method described in JP-A-9-040652 using a fluidized bed granulation coating apparatus (FLO-5 type, manufactured by Freund Corporation). ), Lactose (804.2g, Parmatose, 200M Lactose, DMV International), crystalline cellulose (345.0g, Avicel PH301, Asahi Kasei Corporation) and clospovidone (75.0g, PVPP, XL-10, ISP) ) And mix the mixture with polybutyl alcohol
- the tablet 1 (tablet weight: 130.0 mg, tablet shape: round tablet (7.0 mm)) was obtained by tableting the obtained granules for tableting using (Collect 12, manufactured by Kikusui Seisakusho Co., Ltd.). ⁇ ) was obtained.
- uncoated tablets were prepared as follows. That is, Compound 1 (1153.8 g) obtained according to the method described in Japanese Patent Application Laid-Open No. 9-040652 using a fluidized bed granulation coating apparatus (Dallat WSG-15, manufactured by Pallek Co., Ltd.) , Lactose (8850.0g, Parmatose,
- the sized granules (6930.0 g) and magnesium stearate (70.0 g, HyQual®, manufactured by Marine Clot) Were mixed to obtain granules for tableting.
- the obtained granules for tableting are tableted using a tableting machine (Collect 12, manufactured by Kikusui Seisakusho Co., Ltd.) to obtain uncoated tablets (weight: 130.0 mg, tablet shape: round tablet (7.0 ⁇ )).
- the coating composition prepared according to the formulation shown in Table 2 was dissolved and dispersed in purified water to prepare a coating solution having a solid content of 10% by weight.
- HiCoater HCT-30, Freund Corporation
- the uncoated tablet (1000.0 g) obtained above was dried to 5 parts by weight based on 100 parts by weight of the uncoated tablet.
- the film was coated to give a film-coated tablet.
- Tablets were prepared as follows according to the formulation shown in Table 3 below. That is, Compound 1 (100.0 g) obtained using a stirring granulator (VG-05, manufactured by Pallek Co., Ltd.) and lactose (717.0 g) obtained according to the method described in JP-A-9-040652. g, Parmatose, 200M Lactose, manufactured by DMV), potato starch (150.0g, manufactured by Seki Chemical Co., Ltd.) and hydroxypropylcellulose (20.0g, HPC-L, manufactured by Nippon Soda Co., Ltd.) 7.7 weight of hydroxypropyl cellulose (HPC-L, manufactured by Nippon Soda Co., Ltd.). /.
- the aqueous solution 130.0 g was sprayed and kneaded. After drying, the obtained granulated granules were crushed with a granulator (Comil 197S, manufactured by Pallec Co., Ltd.) to obtain granulated granules.
- a granulator Comil 197S, manufactured by Pallec Co., Ltd.
- the granulated granules (802.1 g) and magnesium stearate (2.4 g, HyQual®, Malin clot) were obtained using a blender (V-type blender V-10, Tokuju Seisakusho Co., Ltd.). Was mixed to obtain granules for tableting.
- a tableting machine (Collect 12, manufactured by Kikusui Seisakusho Co., Ltd.) was used to make the obtained tableting granules into tablets 2 (weight: 200.0 mg, tablet shape: round tablet (8.0 mm)). ⁇ )) was obtained.
- Comparative Example 2 Preparation of Tablet 3 (20 mg, uncoated)
- Tablets were prepared as follows according to the formulation shown in Table 3 below. That is, Compound 1 (200.0 g), lactose (734.0) obtained by a stirrer and granulator (VG-05, manufactured by Pallek Co., Ltd.) according to the method described in JP-A-9-040652. g, Parmatose, 200M Lactose, DMV International), potato starch (300.0g, manufactured by Nisseki Chemical Co., Ltd.) and hydroxypropylcellulose (50.0g, HPC-L, Nippon Soda)
- Tablets were prepared as follows in accordance with the formulation shown in Table 3 below. That is, compound 1 (200.0 g) obtained according to the method described in JP-A-9-040652 using a fluidized bed granulation coating apparatus (FLO-2 type, manufactured by Freund Sangyo Co., Ltd.) , Lactose (697.0g, Parmatose, 200M Lactose, DMV International), partially alpha starch
- HPMC 2910 (TC-5E; manufactured by Shin-Etsu Chemical Co., Ltd.), lactose (Paraiatose, 200M Lactose; manufactured by DMV International), Macrogol 4000 (manufactured by B-Oil & Fat Co., Ltd.), triacetin (organic synthetic chemical Industrial Co., Ltd.), Talc (Ris Blanc; Kihara Kasei Co., Ltd.) Industrial applicability
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004257524A AU2004257524A1 (en) | 2003-07-17 | 2004-07-16 | Solid pharmaceutical preparation |
CA002532093A CA2532093A1 (en) | 2003-07-17 | 2004-07-16 | Solid formulation |
JP2005511923A JP4673745B2 (ja) | 2003-07-17 | 2004-07-16 | 固形製剤 |
US10/515,204 US20060029663A1 (en) | 2003-07-17 | 2004-07-16 | Solid formulation |
EP04747894A EP1647275A4 (en) | 2003-07-17 | 2004-07-16 | SOLID PHARMACEUTICAL PREPARATION |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-198434 | 2003-07-17 | ||
JP2003198434 | 2003-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005007167A1 true WO2005007167A1 (ja) | 2005-01-27 |
Family
ID=34074377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/010530 WO2005007167A1 (ja) | 2003-07-17 | 2004-07-16 | 固形製剤 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20060029663A1 (ja) |
EP (1) | EP1647275A4 (ja) |
JP (1) | JP4673745B2 (ja) |
KR (1) | KR20060033788A (ja) |
CN (1) | CN1822842A (ja) |
AR (1) | AR045909A1 (ja) |
AU (1) | AU2004257524A1 (ja) |
CA (1) | CA2532093A1 (ja) |
TW (1) | TW200507882A (ja) |
WO (1) | WO2005007167A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010530355A (ja) * | 2007-06-21 | 2010-09-09 | 大塚製薬株式会社 | 医薬固形製剤及びその製造方法 |
JP2020186190A (ja) * | 2019-05-13 | 2020-11-19 | 東和薬品株式会社 | イストラデフィリン製剤 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
WO2004099207A1 (ja) * | 2003-05-09 | 2004-11-18 | Kyowa Hakko Kogyo Co. Ltd. | 微細結晶 |
US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
CA2620406A1 (en) * | 2005-09-02 | 2007-03-08 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
EP1924246B1 (en) | 2005-09-15 | 2015-10-21 | Genzyme Corporation | Sachet formulation for amine polymers |
JP2009536246A (ja) * | 2006-05-05 | 2009-10-08 | ゲンズイメ コーポレーション | ホスフェート捕捉剤としてのアミン縮合重合体 |
MX2009000611A (es) * | 2006-07-18 | 2009-04-16 | Genzyme Corp | Dendrimeros de amina. |
BRPI0717545A2 (pt) | 2006-09-29 | 2013-10-22 | Gezyme Corp | Composição farmacêutica, método para tratar uma doença, polímero de amida, rede de polímero, e, método para preparar um polímero de amida |
JP2010513271A (ja) | 2006-12-14 | 2010-04-30 | ゲンズイメ コーポレーション | アミド−アミンポリマー組成物 |
WO2008103368A1 (en) * | 2007-02-23 | 2008-08-28 | Genzyme Corporation | Amine polymer compositions |
US20100196305A1 (en) * | 2007-03-08 | 2010-08-05 | Dhal Pradeep K | Sulfone polymer compositions |
JP2010525061A (ja) * | 2007-04-27 | 2010-07-22 | ゲンズイメ コーポレーション | アミドアミンデンドリマー組成物 |
EP2217215A1 (en) * | 2007-12-14 | 2010-08-18 | Genzyme Corporation | Coated pharmaceutical compositions |
US20110142952A1 (en) * | 2008-06-20 | 2011-06-16 | Harris David J | Pharmaceutical Compositions |
DE102008047910A1 (de) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
AU2009307367B2 (en) * | 2008-10-24 | 2015-04-23 | Toray Industries, Inc. | Stable tablet containing 4,5-epoxymorphinan derivative |
CN113024558A (zh) * | 2021-03-15 | 2021-06-25 | 山东新华制药股份有限公司 | 伊曲茶碱的晶体的制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03258730A (ja) * | 1990-03-07 | 1991-11-19 | Asahi Chem Ind Co Ltd | 顆粒含有錠 |
JPH06211856A (ja) * | 1992-09-28 | 1994-08-02 | Kyowa Hakko Kogyo Co Ltd | パーキンソン氏病治療剤 |
JP2000273038A (ja) * | 1999-01-20 | 2000-10-03 | Taisho Pharmaceut Co Ltd | 口腔内溶解性錠剤 |
JP2002255797A (ja) * | 2000-12-28 | 2002-09-11 | Eisai Co Ltd | 鋳型錠 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4753801A (en) * | 1985-10-25 | 1988-06-28 | Eli Lilly And Company | Sustained release tablets |
DE3843117A1 (de) * | 1988-12-22 | 1990-06-28 | Boehringer Ingelheim Kg | Neue xanthinderivate mit adenosin-antagonistischer wirkung |
SE9002017D0 (sv) * | 1990-06-06 | 1990-06-06 | Kabivitrum Ab | Process for manufacture of matrices |
US5484920A (en) * | 1992-04-08 | 1996-01-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for Parkinson's disease |
US5877180A (en) * | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
US5807580A (en) * | 1996-10-30 | 1998-09-15 | Mcneil-Ppc, Inc. | Film coated tablet compositions having enhanced disintegration characteristics |
US20030215499A1 (en) * | 2002-05-14 | 2003-11-20 | Yong-Cheng Shi | Use of completely linear short chain alpha-glucans as a pharmaceutical excipient |
WO2004099207A1 (ja) * | 2003-05-09 | 2004-11-18 | Kyowa Hakko Kogyo Co. Ltd. | 微細結晶 |
-
2004
- 2004-06-28 TW TW093118711A patent/TW200507882A/zh unknown
- 2004-07-14 AR ARP040102471A patent/AR045909A1/es not_active Application Discontinuation
- 2004-07-16 KR KR1020067000594A patent/KR20060033788A/ko not_active Application Discontinuation
- 2004-07-16 EP EP04747894A patent/EP1647275A4/en not_active Withdrawn
- 2004-07-16 WO PCT/JP2004/010530 patent/WO2005007167A1/ja active Application Filing
- 2004-07-16 JP JP2005511923A patent/JP4673745B2/ja active Active
- 2004-07-16 AU AU2004257524A patent/AU2004257524A1/en not_active Abandoned
- 2004-07-16 US US10/515,204 patent/US20060029663A1/en not_active Abandoned
- 2004-07-16 CN CNA2004800203246A patent/CN1822842A/zh active Pending
- 2004-07-16 CA CA002532093A patent/CA2532093A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03258730A (ja) * | 1990-03-07 | 1991-11-19 | Asahi Chem Ind Co Ltd | 顆粒含有錠 |
JPH06211856A (ja) * | 1992-09-28 | 1994-08-02 | Kyowa Hakko Kogyo Co Ltd | パーキンソン氏病治療剤 |
JP2000273038A (ja) * | 1999-01-20 | 2000-10-03 | Taisho Pharmaceut Co Ltd | 口腔内溶解性錠剤 |
JP2002255797A (ja) * | 2000-12-28 | 2002-09-11 | Eisai Co Ltd | 鋳型錠 |
Non-Patent Citations (2)
Title |
---|
See also references of EP1647275A4 * |
WADA, Y. ET AL.: "Funtai no Asshukusei ni Taisuru Fuchaku Seibun no Eikyo -Kyushitsu Funmatsu o Mochiita Seizoho no Sekkei to sono Kiso Kenkyu", JOURNAL OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY, JAPAN, vol. 50, no. 2, 1990, pages 215 - 224, XP002985328 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010530355A (ja) * | 2007-06-21 | 2010-09-09 | 大塚製薬株式会社 | 医薬固形製剤及びその製造方法 |
US10905694B2 (en) | 2007-06-21 | 2021-02-02 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical solid preparation comprising benzazepines and production method thereof |
JP2020186190A (ja) * | 2019-05-13 | 2020-11-19 | 東和薬品株式会社 | イストラデフィリン製剤 |
JP7382737B2 (ja) | 2019-05-13 | 2023-11-17 | 東和薬品株式会社 | イストラデフィリン製剤 |
Also Published As
Publication number | Publication date |
---|---|
JP4673745B2 (ja) | 2011-04-20 |
EP1647275A4 (en) | 2008-12-10 |
US20060029663A1 (en) | 2006-02-09 |
CN1822842A (zh) | 2006-08-23 |
CA2532093A1 (en) | 2005-01-27 |
EP1647275A1 (en) | 2006-04-19 |
KR20060033788A (ko) | 2006-04-19 |
TW200507882A (en) | 2005-03-01 |
JPWO2005007167A1 (ja) | 2006-08-31 |
AU2004257524A1 (en) | 2005-01-27 |
AR045909A1 (es) | 2005-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005007167A1 (ja) | 固形製剤 | |
CA2726472C (en) | Solid pharmaceutical formulations comprising bibw 2992 | |
US11413295B2 (en) | Oral preparation of obeticholic acid | |
US8420662B2 (en) | Stable solid preparation containing 4,5-epoxymorphinan derivative | |
US20240075039A1 (en) | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor | |
CA2651138C (en) | Pharmaceutical composition | |
TR201802379T4 (tr) | 4,5-epoksimorfinan türevi içeren stabil tablet. | |
JP2024009815A (ja) | アキシチニブを含有する医薬組成物 | |
JP2010195836A (ja) | 微細結晶 | |
WO2007090595A1 (en) | Solid formulations of valacyclovir hydrochloride | |
WO2005065662A1 (en) | Solid dosage formulations of galantamine | |
JP4413866B2 (ja) | ジアリールビニレン化合物の安定化方法 | |
JP2011126857A (ja) | パロキセチン塩酸塩含有経口用錠剤 | |
KR102322429B1 (ko) | 수니티닙을 함유하는 경구용 제제 및 그의 제조 방법 | |
JP5563371B2 (ja) | クエチアピンフマル酸塩含有経口用錠剤 | |
JP2017132724A (ja) | アムロジピン含有被覆造粒物を含む配合口腔内崩壊錠 | |
KR20210077626A (ko) | 수니티닙 염산염을 포함하는 경구용 고형제제 및 그 제조 방법 | |
WO2024115680A1 (en) | Ribociclib salts and formulations thereof | |
TW201244757A (en) | Solid preparation | |
JPWO2019194095A1 (ja) | ソリフェナシン含有医薬組成物 | |
EP1713451A1 (en) | Solid dosage formulations of galanthamine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480020324.6 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2006029663 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10515204 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005511923 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004257524 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004747894 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004257524 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2532093 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067000594 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10515204 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004747894 Country of ref document: EP Ref document number: 1020067000594 Country of ref document: KR |